Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 8—August 2024
Research Letter

Panton-Valentine Leukocidin–Positive Staphylococcus aureus in Family and Pet Cat

Astrid Bethe, Anne-Kathrin Schink, Julian Brombach, Lennard Epping, Torsten Semmler, Susanne Reinhardt, Ernst Molitor, Svenja Müller, Julian Balks, Robin Köck, Stefan Schwarz, Birgit Walther1, and Antina Lübke-Becker1Comments to Author 
Author affiliations: Freie Universität Berlin, Berlin, Germany (A. Bethe, A.-K. Schink, J. Brombach, S. Schwarz, A. Lübke-Becker); German Environment Agency, Berlin (A. Bethe, B. Walther); Laboratory Diagnostics Germany, Cuxhaven, Germany (A.-K. Schink); Robert Koch Institute, Berlin (L. Epping, T. Semmler, B. Walther); Kleintierpraxis am Kenntemichplatz, Troisdorf, Germany (S. Reinhardt); University Hospital, Bonn, Germany (E. Molitor, S. Müller, J. Balks); Universitätsmedizin, Essen, Germany (R. Köck)

Main Article

Table

Antimicrobial susceptibility testing results of Staphylococcus aureus isolates recovered from a family who had repeated soft-tissue infections caused by Panton-Valentine leukocidin–producing S. aureus and their pet cats*

Isolate IMT51844 IMT51843 IMT51535 IMT51669 IMT51533 IMT51534 IMT51668 IMT51681
Source Child Parent Cat 2 Cat 2 Cat 1 Cat 1 Cat 1 Cat 1
Sample site Nose Inguinal Mouth Nose Mouth Nose Nose Nose
Date 2021 Nov 2021 Nov 2022 Mar 2022 Mar 2022 Mar 2022 Mar 2022 Mar 2022 Mar
ST 45 8 45 45 8 8 8 8
PVL
 –
 +
 –
 –
 +
 +
 +
 +
Antimicrobial drug MIC, µg/mL
CIP 0.12 16 0.12 0.25 16 16 16 16
ENR 0.12 4 0.12 0.12 4 4 4 4
MAR 0.25 16 0.25 0.25 16 16 16 16
GEN 1 0.25 0.5 1 0.25 0.25 1 0.25
SXT 0.06/1.19 0.06/1.19 0.06/1.19 0.06/1.19 0.06/1.19 0.06/1.19 0.06/1.19 0.06/1.19
TET 0.25 32 0.5 1 64 32 32 64
DOX 0.5 4 0.5 0.5 4 4 4 4
PEN 0.03 0.03 0.03 0.03 0.03 0.06 0.06 0.06
AMP 0.12 0.12 0.25 0.12 0.12 0.12 0.25 0.25
AMC 0.25/0.12 0.25/0.12 0.25/0.12 0.25/0.12 0.25/0.12 0.25/0.12 0.25/0.12 0.25/0.12
OXA 0.12 0.25 0.12 0.25 0.25 0.25 0.5 0.25
ERY 1 >64 0.5 0.5 >64 32 >64 >64
CLI 0.25 0.25 0.25 0.25 0.12 0.12 0.25 0.12

*AMC, amoxicillin/clavulanate; AMP, ampicillin; CIP, ciprofloxacin; CLI, clindamycin; DOX, doxycycline; ENR, enrofloxacin; ERY, erythromycin; GEN, gentamicin; MAR, marbofloxacin; OXA, oxacillin; PEN, penicillin; PVL, Panton-Valentine leukocidin; ST, sequence type; SXT, sulfamethoxazole/trimethoprim; TET, tetracycline; +, positive; –, negative.

Main Article

1These authors contributed equally to this article.

Page created: June 28, 2024
Page updated: July 02, 2024
Page reviewed: July 02, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external